sortium will evaluate these modified allergens in human clinical trials led by Robert Wood, M.D., of the Johns Hopkins University School of Medicine, Baltimore.
The consortium's second project is an observational study that will enroll 400 infants who have allergies to milk or eggs. Such children are at higher risk of developing peanut allergy, but the vast majority will lose their allergies to those foods as they grow up. The study will follow the children for at least five years and study immunologic changes that accompany the loss of allergy to foods and the development of allergy to new foods. This study will be led by Scott Sicherer, M.D., at Mount Sinai School of Medicine.
The clinical and observational studies will take place at five clinical sites:
- Mount Sinai School of Medicine, New York; Principal Investigator: Hugh Sampson, M.D.
- Johns Hopkins University School of Medicine, Baltimore; Principal Investigator: Robert Wood, M.D.
- Duke University School of Medicine, Durham, NC; Principal Investigator: Wesley Burks, M.D.
- University of Arkansas Children's Hospital Research Institute, Little Rock; Principal Investigator: Stacie Jones, M.D.
- National Jewish Medical and Research Center, Denver; Principal Investigator: Donald Leung, M.D., Ph.D.
For information about participating in the Food Allergy Research Consortium's clinical and observational studies, please call the Mount Sinai School of Medicine Pediatric Allergy Division at 212-241-5548.
The consortium's third project will conduct basic immunobiology research to determine the biological mechanisms of peanut allergy in mice. This knowledge will provide insights into allergic mechanisms in humans, which will lead to the identification and development of potential strategies to treat and prevent food allergies in humans. This research will be led by Kim Bottomly, Ph.D., of Yale University, New Haven, CT, in collaboration with DPage: 1 2 3 Related medicine news :1
Contact: Linda Joy
NIH/National Institute of Allergy and Infectious Diseases
. Vacuum cleaning ineffective in allergy avoidance2
. World-leading innovation in child-allergy detection3
. Study shows six-injection allergy vaccine tames hay fever for at least 2 years4
. New allergy vaccine provides long-lasting hay fever relief after just 6 weeks of shots5
. Experimental ragweed therapy offers allergy sufferers longer relief with fewer shots6
. Prebiotics can cut development of skin allergy in babies at high risk7
. Researchers demonstrate potential mechanism of food allergy8
. Desensitization protocol overcomes allergy to clopidogrel9
. Evidence of estrogen and progesterone hormone allergy has been discovered by Texas researchers10
. New labelling on foods still not clear enough for allergy sufferers11
. Some outgrow allergy to tree nuts, Johns Hopkins Childrens Center experts report